Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630838 · ClinicalTrials.gov registry record · Phase 2
Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)
A Phase 2 study of Hirschsprung Disease, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 2
- Study locations
NCT00630838 is a Phase 2 study of Hirschsprung Disease that has completed, run by University of Michigan. The registered enrollment target is 62 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00630838, a Phase 2 study of Hirschsprung Disease, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prospective, randomized, controlled trial to test if post-operative administration of probiotics in HD patients will lead to a reduction in the occurrence of HAEC.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VSL#3
Study Locations (2)
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
New York
- Children's Hospital of Buffalo - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630838
The ClinicalTrials.gov registry entry for NCT00630838 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hirschsprung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00630838 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT00630838 about?
NCT00630838 is a clinical study titled "Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)". Prospective, randomized, controlled trial to test if post-operative administration of probiotics in HD patients will lead to a reduction in the occurrence of HAEC.
What is the current status of trial NCT00630838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2006-09. Estimated completion is 2010-09.
What conditions does trial NCT00630838 study?
This clinical trial studies the following conditions: Hirschsprung Disease.
What interventions are being tested in trial NCT00630838?
The interventions under investigation include: Placebo (DRUG), VSL#3 (DRUG).
Who is sponsoring clinical trial NCT00630838?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00630838 being conducted?
This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hirschsprung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.